# US 2022/0031819 A1 · Compositions for inhibiting teratoma formation and growth comprising timp-1 and timp-2 as effective components

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031819 A1
- Document ID: US20220031819A1
- Status: Published application
- Kind: A1
- Application number: 17/274,657
- Filed: 2019-07-18
- Published: 2022-02-03
- Earliest claimed: 2018-09-10
- Assignees: Korea University Research and Business Foundation
- Applicants: Korea University Research and Business Foundation
- Inventors: Sung Hoi HONG; Kyung-Ah CHOI
- Web page: https://patentgrep.com/patent/US20220031819A1

## CPC

- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a composition for inhibiting teratoma formation or growth, comprising tissue inhibitor of metalloproteinase 1 (TIMP-1) or tissue inhibitor of metalloproteinase 2 (TIMP-2) as an effective component. A pharmaceutical composition for inhibiting teratoma formation or growth comprising TIMP-1 or TIMP-2 as an effective component according to the present invention, when used in stem cell therapy, can inhibit the formation and growth of teratomas caused by undifferentiated pluripotent stem cells, without affecting the differentiation potential thereof, and thus can be advantageously used as a combination drug in combination with a stem cell drug.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method for inhibiting teratoma formation or growth comprising administering a composition comprising TIMP-1 or TIMP-2 as an active ingredient to a subject in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, the composition is used in combination with stem cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or adult stem cells.

### Claim 13 (depends on 10)

The method of claim 10, wherein the TIMP-1 or TIMP-2 is derived from neural stem cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the neural stem cells are derived from a brain ventricular zone.

### Claim 15 (depends on 10)

The method of claim 10, the composition is produced by a process comprising steps of:
(a) immortalizing neural stem cells (NSCs) isolated from a brain ventricular zone; and
(b) obtaining TIMP-1 or TIMP-2 in conditioned medium by culturing the immortalized neural stem cells in a non-inducing medium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the non-inducing medium comprises DMEM (Dulbecco's Modified Eagle's Medium), 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin.

### Claim 17

A method for producing a composition for inhibiting teratoma formation or growth comprising TIMP-1 or TIMP-2 as an active ingredient, the method comprising steps of:
(a) immortalizing neural stem cells (NSCs) isolated from a brain ventricular zone; and
(b) obtaining TIMP-1 or TIMP-2 in conditioned medium by culturing the immortalized neural stem cells in a non-inducing medium.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition is used in combination with stem cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or adult stem cells.

### Claim 20 (depends on 17)

The method of claim 17, wherein the non-inducing medium comprises DMEM (Dulbecco's Modified Eagle's Medium), 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin.
